- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
EULAR 2018 | Daily Highlights
Leflunomide for GCA
The role of Leflunomide in the treatment of Giant Cell Arteritis
Abstract: SAT0518
Authors: Hoceva A. et al.
Despite the availability of Tocilizumab to treat GCA, there remains a lack of alternative steroid-sparing agents. Old and more recent reports about Methotrexate do not solve the problem. Little has been published regarding alternatives. Thus, it is of interest that in a centre of Slovenia colleagues have analysed their experience with Leflunomide (LEF).
Key content:
This prospective observational study included newly diagnosed GCA patients which were followed at least 48 weeks. Treatment was started with Prednisone at a dose of 32 – 48mg daily. At week 12 LEF 10mg daily was added to patients not having a contraindication. LEF dose could be increased to 20mg. Of a total of 76 patients, 30 received LEF. Relapse occurred in 22 of patients, 4 in the LEF and 18 in the steroid-only group. 17/30 LEF treated patients could stop steroids, but none in the GC-only group.
Relevance:
Although observational and so far in Abstract form only, the data provide an additional argument to consider LEF as a steroid-sparing agent in GCA.
Zusammenfassung und Kommentar von:
Prof. Dr. Peter Villiger
Bern
